Natural Pregnancy in Non-Obstructive Azoospermia
Understanding Non-Obstructive Azoospermia
- Non-obstructive azoospermia is characterized by the complete absence of sperm in the ejaculate after centrifugation, confirmed by at least two consecutive semen analyses 2
- The condition is associated with low testicular volume, normal sperm volume, and high FSH values, indicating primary testicular dysfunction or hypothalamus-pituitary-gonadal axis dysfunction 2
- Testicular atrophy is common, especially with FSH levels greater than 7.6 IU/L, which is a significant indicator of the severity of the condition 1, 3
Why Natural Pregnancy Is Not Possible
- By definition, NOA means there are no sperm in the ejaculate, making natural conception impossible, as stated by the American Urological Association 1, 2
- The condition represents a severe deficit in spermatogenesis, preventing sperm from appearing in the ejaculate, which is a critical factor in male fertility 2
Treatment Options for NOA
Medical Management (Limited Success)
- Selective estrogen receptor modulators (SERMs), aromatase inhibitors, and gonadotropins may be used prior to surgical intervention to improve hormonal parameters, as recommended by the European Association of Urology 4, 5
Surgical Sperm Retrieval
- Microdissection testicular sperm extraction (micro-TESE) is the recommended surgical approach for NOA, with sperm retrieval rates ranging from 40-60% of NOA cases, according to the American Society for Reproductive Medicine 7
Important Considerations
- Genetic testing is essential as karyotype abnormalities are common causes of NOA, and Y-chromosome microdeletion testing is recommended for men with NOA, as stated by the European Society of Human Genetics 1, 3
- Complete AZFa and AZFb microdeletions make sperm retrieval virtually impossible, highlighting the importance of genetic testing in NOA diagnosis 2
- Exogenous testosterone therapy should be avoided in men with NOA seeking fertility as it further suppresses spermatogenesis, which is a critical consideration in treatment planning, as recommended by the Endocrine Society 4, 6